A new weapon in the global fight against malaria
World Health Organization prequalifies Syngenta’s innovative insecticide Sovrenta®
Malaria is one of the world’s most deadly diseases, and it is becoming more pervasive – despite decades of effort and some successes on the path to eradicating it. According to the World Health Organization (WHO), malaria infected 263 million people and killed nearly 600,000 people in 2023 – 75% of whom were children under the age of 5. Of those afflicted, 94% are in Africa – where malaria crushes communities and can cripple economies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250422328472/en/
Syngenta Vector Control: A leading role in the prevention of vector-borne disease transmission through its portfolio of mosquito control products
Spread by parasites in infected mosquitoes that are highly adept at evolving, malaria’s rise reflects the reality of insecticide resistance and the difficulties developing new solutions. The effective control of mosquitoes remains a key strategy for reducing disease transmission.
Syngenta, a global leader in agricultural innovation, today announced that its next-generation insecticide Sovrenta® has received pre-qualification by WHO, paving the way for its use in malaria-afflicted countries. For decades, Syngenta has been at the forefront of the fight against malaria, reflecting its commitment to researching new solutions through in-house R&D efforts and working alongside key partners across sub-Saharan Africa; its products such as Actellic® already help avert as many as 100 million cases of malaria in more than 30 countries.
Sovrenta® works by targeting a mosquito’s nervous system, blocking signals that enable the insect’s muscles to relax. The effect paralyzes the mosquito, so that it eventually dies. The ability of Sovrenta® to provide long-lasting, effective control means just one application is required each season, reducing the cost for malaria prevention programs.
Sovrenta® is based on Syngenta’s cutting-edge PLINAZOLIN® technology that features a new mode of action, ensuring effective control of mosquitoes even where the insect’s populations are increasingly resistant to older insecticides. When used in rotation with other products, Sovrenta® can further ensure that important vector control solutions remain effective for longer.
Andy Bywater, Global Head of Marketing for Vector Control at Syngenta Crop Protection, said: “This marks an important milestone in Syngenta’s quest to bring its most advanced innovations to malaria-endemic countries, and to advancing the health and safety of the millions still at risk.”
Bywater said Sovrenta® is a crucial addition to Syngenta’s vector control portfolio that allows for enhanced resistance-management strategies. That is key in regions where mosquitoes are resistant to older insecticides based on pyrethroids – the most common forms of treatment. “Sovrenta® is the only insecticide recognized to provide year-long protection and gives malaria control programs a powerful tool to safeguard communities,” Bywater said. “We are dedicated to collaborating with partners to ensure Sovrenta® is deployed sustainably and effectively.”
The WHO’s Vector Control Product Pre-Qualification (VCPP) is a rigorous process that ensures the safety, efficacy, and quality of vector-borne disease control products. Its list of prequalified vector control products is used by international procurement agencies and by countries to guide bulk purchasing of these products for distribution in resource-limited countries.
Web Resources
Media release image pack
Syngenta Media Library
About Syngenta
Syngenta is a global leader in agricultural innovation with a presence in more than 90 countries. Syngenta is focused on developing technologies and farming practices that empower farmers, so they can make the transformation required to feed the world’s population while preserving our planet. Its bold scientific discoveries deliver better benefits for farmers and society on a bigger scale than ever before. Guided by its Sustainability Priorities, Syngenta is developing new technologies and solutions that support farmers to grow healthier plants in healthier soil with a higher yield. Syngenta Crop Protection is headquartered in Basel, Switzerland; Syngenta Seeds is headquartered in the United States. Read our stories and follow us on LinkedIn, Instagram & X.
Syngenta Vector Control plays a leading role in the prevention of vector-borne disease transmission through its portfolio of mosquito control products. Visit our website and follow us on LinkedIn & X.
Data protection is important to us. You are receiving this publication on the legal basis of Article 6 para 1 lit. f GDPR (“legitimate interest”). However, if you do not wish to receive further information about Syngenta, just send us a brief informal message and we will no longer process your details for this purpose. You can also find further details in our privacy statement.
Cautionary Statement Regarding Forward-Looking Statements
This document may contain forward-looking statements, which can be identified by terminology such as ‘expect’, ‘would’, ‘will’, ‘potential’, ‘plans’, ‘prospects’, ‘estimated’, ‘aiming’, ‘on track’ and similar expressions. Such statements may be subject to risks and uncertainties that could cause the actual results to differ materially from these statements. For Syngenta, such risks and uncertainties include risks relating to legal proceedings, regulatory approvals, new product development, increasing competition, customer credit risk, general economic and market conditions, compliance and remediation, intellectual property rights, implementation of organizational changes, impairment of intangible assets, consumer perceptions of genetically modified crops and organisms or crop protection chemicals, climatic variations, fluctuations in exchange rates and/or commodity prices, single source supply arrangements, political uncertainty, natural disasters, and breaches of data security or other disruptions of information technology. Syngenta assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.
©2025 Syngenta. Rosentalstrasse 67, 4058 Basel, Switzerland.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250422328472/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Veracode Advances Application Risk Management with Innovations for Comprehensive Risk Visibility and Software Supply Chain Security22.4.2025 13:50:00 CEST | Press release
Strategic Enhancements to Veracode Risk Manager and Package Firewall Deliver Unified Security and Risk Prioritization Veracode, a global leader in application risk management, today unveiled new capabilities offering proactive risk mitigation and automated security at enterprise scale. With software supply chain attacks and open-source vulnerabilities at an all-time high, enhanced Veracode Risk Manager (VRM) and an early access program for Veracode Package Firewall come at a critical juncture. The innovations represent a significant milestone in Veracode’s vision to deliver centralized risk visibility and secure development from the start. “Security teams face immense pressure to combat evolving threats, while developers require the flexibility to innovate quickly,” said Derek Maki, Head of Product at Veracode. “Our latest Application Risk Management platform enhancements provide organizations with the tools to not just identify risks, but to trace them to their root cause and prevent
Antibody Solutions Launches Single Plasma B-Cell Services through Cellestive Discovery Platform22.4.2025 13:00:00 CEST | Press release
New, exclusive capability will allow antibody discovery clients to access more hits and more screening data than competing technologies Antibody Solutions, a leading provider of fit-for-purpose antibody discovery services, announced today that for the first time, single plasma B-cell discovery services will be part of the company’s exclusive Cellestive antibody discovery platform. The new capability completes a trifecta of B-cell services offered through Cellestive, which already includes discovery pathways for both activated and memory B-cells. The new plasma B-cell service is projected to be of particular value to clients pursuing difficult targets in antibody discovery, enabling them to leverage new processes and technologies while accessing broader, deeper data to inform their decision-making. “This really rounds out our Cellestive platform and allows us to robustly and efficiently interrogate single plasma B-cells for our clients,” said John Kenney, Phd, co-founder and president o
Sun Nuclear Announces Completion of Transition to CE Class IIb EU MDR Certification for Key Quality Management Solutions22.4.2025 12:04:00 CEST | Press release
SunCHECK® Software, SRS MapCHECK® and SunSCAN™ 3D DevicesAmong 15+ Solutions Awarded New Certification Sun Nuclear, a Mirion Medical company, announced today that its SunCHECK® Quality Management software and key radiation therapy Quality Assurance (QA) devices have been awarded CE Class IIb certification under the European Medical Devices Regulation 2017/745 (EU MDR). The transition to EU MDR Class IIb recognizes the safety and performance of Sun Nuclear solutions and confirms compliance with stringent safety requirements. Sun Nuclear solutions awarded Class IIb certification include: The SunCHECK® Platform, a comprehensive software application facilitating essential Patient and Machine QA workflows and centralized data management; Patient-specific QA solutions, including the ArcCHECK®, ArcCHECK®-MR, MapCHECK® 3 and SRS MapCHECK® devices, for measurement of radiation dose distributions against planned doses; Machine QA solutions, including the Daily QA™ 3, Daily QA™ 3-MR, IC PROFILER™
Regula Becomes the First to Verify All Dynamic Security Features in Remote Document Checks22.4.2025 12:00:00 CEST | Press release
With the recent update of its Document Reader SDK, Regula became the first identity verification (IDV) vendor to make it possible to verify all the dynamic security features of documents in real time. With the latest addition of Dynaprint® checks, the solution ensures more robust physical document authentication during remote onboarding. The innovation has arrived at a time when 58% of businesses globally face fake or modified IDs during digital onboarding. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250422724077/en/ Dynaprint in the Arizona’s driver’s license (Photo: Regula) Dynaprint® is a dynamic security feature consisting of two different images printed with lenticular technology. Depending on the angle of observation, only one image is visible at a time. Like all other dynamic security features, Dynaprint is crucial for securing identity documents from tampering, since it’s a tricky task to fake it without special e
Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression22.4.2025 12:00:00 CEST | Press release
Highlights: Participants received a single dose of either 25 mg of COMP360 or placebo On track for disclosure of top-line 6-week primary endpoint results in late June Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that all participants have completed dosing in Part A of the COMP005 phase 3 trial for treatment resistant depression (TRD). Following pre-dosing activities, including washout from anti-depressant medications, if needed, participants received a single dose of either 25 mg of COMP360 or placebo. The Company is on track to disclose top-line 6-week primary endpoint results in late June. “Completing dosing of all participants in Part A of our 005 trial marks a critical milestone in our mission to address the pressing unmet need in treatment resistant depression,” said Kabir Nath, CEO Compass Pathways. “We are proud of this achievement which reflects our team’s commitment to scient
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom